Forgot Password?
Return to Course Listing

CME: Interstitial Lung Disease with Progressive Lung Disease Phenotype (ILD-PF): Therapeutic Updates, Best Practices, and Emerging Therapies

Activity Description / Statement of Need:

In this online, self-learning activity:

Interstitial lung disease (ILD) is a collective term used to categorize more than 200 different types of diseases that affect the alveolar structures, the pulmonary interstitium, and small airways. The incidence and prevalence of ILD, as its own entity, are difficult to quantify because of number of different causes and the difficulty diagnosing patients. One form of ILD is associated with an overexpression of adenosine-2B receptor (A2BAR) has been linked to rapid progression of idiopathic pulmonary fibrosis (IPF), a type of IIP, and patients identified with this highly upregulated gene warrants closer monitoring of lung function and disease progression. Known as ILD with progressive lung phenotype (ILD-PF), patients with a number of diseases, such as rheumatoid arthritis and chronic hypersensitivity pneumonitis, are predisposed to this variant. This learning activity has been designed to bring HCPs’ knowledge of the strategies for treatment and management of ILD-PF up to date and to improve their competence and performance in treating it.

Target Audience:

The following HCPs: pulmonologists, rheumatologists, primary care physicians, pathologists, dermatologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in pulmonology; and any other HCPs who have an interest in or otherwise clinically encounter patients with ILD-PF.


This program is supported by an educational grant from Boehringer Ingelheim.


Release Date: January 27, 2019 -- Expiration Date: January 27, 2021

Faculty: Terese Hammond, MD

Agenda

Introduction, Disclosures

Cursory refresher and review on ILD epidemiology and diagnosis and introduction to the PF variant

  • Epidemiology, risk factors, and pathophysiology

o    Age, race, gender

o    Environmental factors

o    Genetics (A2BAR)

o    Autoimmune diseases

o    Immune dysfunction

o    Overactivation of fibroblasts

  • Clinical presentation

o    Dyspnea on exertion

o    Nonproductive cough

·         Diagnosis

o    HRCT scan vs. chest radiography

o    Lung biopsy

o    Serological testing

  • Patient case(s)

Treatment of ILD-PF

  • Treatment overview and goals of therapy
  • Current practice guidelines and standard care options
  • Pharmacogenetics
  • Pharmacotherapy

o    Corticosteroids

o    Immunomodulators

o    Nintedanib

o    Pirfenidone

  • Lung transplantation
  • Patient education
  • Patient case(s)

Summary, conclusions, and best practice recap

1

Introduction, Disclosures

13

Cursory refresher and review on ILD epidemiology and diagnosis and introduction to the PF variant [Learning Objectives #1-3]

  • Epidemiology, risk factors, and pathophysiology

o    Age, race, gender

o    Environmental factors

o    Genetics (A2BAR)

o    Autoimmune diseases

o    Immune dysfunction

o    Overactivation of fibroblasts

  • Clinical presentation

o    Dyspnea on exertion

o    Nonproductive cough

·         Diagnosis

o    HRCT scan vs. chest radiography

o    Lung biopsy

o    Serological testing

  • Patient case(s)

45

Treatment of ILD-PF [Learning Objectives #4 & 5]

  • Treatment overview and goals of therapy
  • Current practice guidelines and standard care options
  • Pharmacogenetics
  • Pharmacotherapy

o    Corticosteroids

o    Immunomodulators

o    Nintedanib

o    Pirfenidone

  • Lung transplantation
  • Patient education
  • Patient case(s)

1

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the pathophysiology of and risk factors for ILD-PF such that it might inform treatment mechanisms and strategies
  • Identify signs and symptoms of ILD-PF (e.g., rheumatoid arthritis, chronic hypersensitivity pneumonitis, unclassified ILD)
  • Describe the prevalence, morbidity, and mortality, burden of illness associated with ILD-PF and, conversely, the benefits associated with early identification and treatment
  • Describe current treatment standards and monitoring parameters (HRCT, PFTs) of ILD-PF, including developments in clinical research and treatment guidelines, and apply them to patient cases
  • Discuss ways to improve clinician communication with their patients, including disease education

Accreditation

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosures:

Dr. Terese C. Hammond,  MD, Clinical Professor, University of Southern California, Los Angeles, CA has no relevant conflicts of interest to disclose.

Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.

Commercial Support Disclosure: This program is supported by an educational grant from Boehringer Ingelheim.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Frontiers in the treatment of systemic sclerosis interstitial lung disease: Therapeutic updates and best practices

The Current and Emerging Landscape of Pharmacotherapy for Neonatal Respiratory Distress Syndrome (NRDS)